Details for Patent: 9,655,843
✉ Email this page to a colleague
Which drugs does patent 9,655,843 protect, and when does it expire?
Patent 9,655,843 protects BELBUCA and BUNAVAIL and is included in two NDAs.
This patent has forty-four patent family members in twenty-four countries.
Summary for Patent: 9,655,843
Title: | Transmucosal delivery devices with enhanced uptake |
Abstract: | The present invention provides methods for enhancing transmucosal uptake of a medicament, e.g., fentanyl or buprenorphine, to a subject and related devices. The method includes administering to a subject a transmucosal drug delivery device comprising the medicament. Also provided are devices suitable for transmucosal administration of a medicament to a subject and methods of their administration and use. The devices include a medicament disposed in a mucoadhesive polymeric diffusion environment and a barrier environment. |
Inventor(s): | Finn; Andrew (Raleigh, NC), Vasisht; Niraj (Cary, NC) |
Assignee: | BioDelivery Sciences International, Inc. (Raleigh, NC) |
Application Number: | 15/212,912 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,655,843 |
Patent Claim Types: see list of patent claims | Use; Delivery; Device; |
Drugs Protected by US Patent 9,655,843
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bdsi | BELBUCA | buprenorphine hydrochloride | FILM;BUCCAL | 207932-001 | Oct 23, 2015 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE | ⤷ Sign Up | |||
Bdsi | BELBUCA | buprenorphine hydrochloride | FILM;BUCCAL | 207932-002 | Oct 23, 2015 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE | ⤷ Sign Up | |||
Bdsi | BELBUCA | buprenorphine hydrochloride | FILM;BUCCAL | 207932-003 | Oct 23, 2015 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE | ⤷ Sign Up | |||
Bdsi | BELBUCA | buprenorphine hydrochloride | FILM;BUCCAL | 207932-004 | Oct 23, 2015 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG-TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,655,843
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2007275581 | ⤷ Sign Up | |||
Brazil | 122020000250 | ⤷ Sign Up | |||
Brazil | PI0714712 | ⤷ Sign Up | |||
Canada | 2658585 | ⤷ Sign Up | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |